MX2017013390A - Método para el tratamiento de cáncer pulmonar. - Google Patents

Método para el tratamiento de cáncer pulmonar.

Info

Publication number
MX2017013390A
MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A
Authority
MX
Mexico
Prior art keywords
fra
patient
lung cancer
level
methods
Prior art date
Application number
MX2017013390A
Other languages
English (en)
Inventor
John O'shannessy Daniel
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of MX2017013390A publication Critical patent/MX2017013390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

se proporcionan en el presente documento métodos para predecir una probabilidad de respuesta al tratamiento con un agente de direccionamiento del receptor alfa de folato (FRA) en un paciente que tiene un cáncer de pulmón que expresa FRA; también se proporcionan métodos para tratar un cáncer de pulmón que expresa FRA en un paciente con un agente de direccionamiento de FRA; los métodos implican cuantificar o determinar el nivel de expresión de FRA del paciente en una muestra biológica y comparar el nivel de expresión de FRA del paciente con un estándar de referencia utilizado para cuantificar el nivel de expresión de FRA, en donde es probable que el paciente responda al tratamiento con el agente de direccionamiento de FRA si el nivel de expresión de FRA del paciente es igual o superior al nivel de expresión de FRA de referencia; también se proporcionan kits relacionados para la predicción de la respuesta y el tratamiento de la población identificada de pacientes con cáncer de pulmón que expresa FRA.
MX2017013390A 2015-04-17 2016-04-14 Método para el tratamiento de cáncer pulmonar. MX2017013390A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (1)

Publication Number Publication Date
MX2017013390A true MX2017013390A (es) 2018-06-13

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013390A MX2017013390A (es) 2015-04-17 2016-04-14 Método para el tratamiento de cáncer pulmonar.

Country Status (13)

Country Link
US (1) US20180125970A1 (es)
EP (1) EP3283886B1 (es)
JP (1) JP2018516244A (es)
KR (1) KR20170137848A (es)
CN (1) CN107624071A (es)
AU (1) AU2016248222A1 (es)
BR (1) BR112017022320A2 (es)
CA (1) CA2983126A1 (es)
IL (1) IL255079A0 (es)
MX (1) MX2017013390A (es)
RU (1) RU2718780C9 (es)
SG (1) SG11201708546UA (es)
WO (1) WO2016168440A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
EP3153178A4 (en) * 2014-06-06 2017-12-20 Kyowa Hakko Kirin Co., Ltd. Method for treating cancer patients using folr1 targeted drug and antifolate, and drug
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
MA52300A (fr) * 2018-06-18 2021-04-21 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
IL314452A (en) * 2022-03-11 2024-09-01 Astrazeneca Ab Scoring method for anti-frα antibody-drug treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
AU2011323124C1 (en) 2010-11-05 2016-09-22 Eisai Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
PL2731972T3 (pl) * 2011-07-15 2018-06-29 Eisai R&D Management Co., Ltd. Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania

Also Published As

Publication number Publication date
IL255079A0 (en) 2017-12-31
US20180125970A1 (en) 2018-05-10
WO2016168440A1 (en) 2016-10-20
EP3283886B1 (en) 2020-01-15
RU2718780C9 (ru) 2020-07-08
AU2016248222A1 (en) 2017-11-09
BR112017022320A2 (en) 2018-07-24
RU2718780C2 (ru) 2020-04-14
SG11201708546UA (en) 2017-11-29
CN107624071A (zh) 2018-01-23
RU2017136863A (ru) 2019-05-17
JP2018516244A (ja) 2018-06-21
EP3283886A1 (en) 2018-02-21
RU2017136863A3 (es) 2019-08-21
CA2983126A1 (en) 2016-10-20
KR20170137848A (ko) 2017-12-13

Similar Documents

Publication Publication Date Title
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
MX2023010805A (es) Metodos terapeuticos y de diagnostico para el cancer.
MX2021009682A (es) Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos.
MX2022006589A (es) Predictor de respuesta de platino pan-cancer.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
MX2018010361A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2019010150A (es) Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5.
ES2721639T3 (es) Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
MX392774B (es) Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
MX2017006242A (es) Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
CL2020001936A1 (es) Métodos para el tratamiento de la atrofía muscular espinal.
BR112019025056A2 (pt) Inibidores de fgfr2 para o tratamento de colangiocarcinoma
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
ES2530732T3 (es) Procedimientos de diagnóstico para el cáncer de pulmón
BR112016017926A2 (pt) ensaio para detectar periostina humana
ES2571111T3 (es) Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia
BR112017012287A2 (pt) uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EISAI INC.